The drug industry is headed back to Congress to make its case. Will Democrats keep the door open?

WASHINGTON — With annual revenues of roughly $450 million and an army of some 160 lobbyists, PhRMA has long been described in near mythological terms by both awed opponents and reverent allies: It’s untouchable, it never loses, it can kill a bill before the ink is dry on the first draft.

Suddenly, however, the industry lobbying powerhouse looks far more vulnerable.